Clinical Trial Search

Primary: Change in Visual Analogue Scale for Major Nasal Symptoms — 3.66; 4.29; 4.49; 5.6 score on a scale

Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts

Primary: Change in Total Symptom Score — -5; 2 score on a scale

Primary: The Change From Baseline in the Mean of the 3 Single Symptom Scores (Blocked Nose, Sneezing and Running Nose) at the Closing/Final Visit. — -2 units on a scale

Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants

Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score

Primary: Net Proportional Change in Nasal Airway Resistance — 0.11; 0.04 proportional change (unit-less)

Primary: Mean Change From Baseline in Daily rTNSS Over the Entire Treatment Period (28 Days) — -2.10; -2.17 points on a scale — p=0.845

Primary: Nasal Congestion as Assessed by the Peak Nasal Inspiratory Flow (PNIF) — 90 Liters Per Minute

Primary: Change in Subjective Nasal Scoring — 0.62; 1.53 score on a scale — p=0.013

Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05

Primary: Change in Reflective Total Nasal Symptom Score (rTNSS) — -5.1 units on a scale — p=<0.0001

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…

Primary: Mean Total Symptom Score (TSS) Elicited by a 1 Hour (h) Cold Dry Air (CDA) Challenge, 1 h and 24 h on Day 14 to Compare the Effect of 14 Day Repeat Dosing of Intranasal…

Primary: Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge — 6; 19.6 milligrams

Primary: Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8 — 6.53; 3.65; 6.57; 4.14 Score on scale

Primary: Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks — 7.84; 8.41; 8.27; 8.29 Units on a scale — p=0.0001

Primary: Total Nasal Symptom Scores — 3.0; 3.1 score on a scale — p=0.45

Primary: Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry — 0.760; 0.742; 0.717; 0.795 ratio — p=0.302

Primary: Total Nasal Symptom Score (TNSS) — 67.1; 78.0 score on a scale — p=0.391

Primary: Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period — -2.0; -1.0 units on a scale…

Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points

Primary: Baseline Adjusted Area Under the Curve (AUC) of Minimal Cross-Sectional Area (MCA) of Nasal Cavity by Acoustic Rhinometry — -0.682; -0.504; -0.550 square centimeter*hour…

Primary: Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment — -.5277; -.5484; -.8359; -.181 score on a scale

Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001

Primary: Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period — -2.5; -1.6 units on a scale — p=<0.001

Primary: Weighted Mean of the Total Nasal Symptom Score (TNSS) (0-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 8 — 5.190; 4.071; 3.840 Scores on a scale — p=<0.0001

Primary: Change From Baseline in the Total Nasal Symptom Score (TNSS) at 15 Minutes After the First Allergan Challenge — 2.90; 3.69 units on a scale — p=0.156

Primary: Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction — 1.38; 1.67 units on a scale

Primary: Asthma Control Test (ACT) — 2.95; 2.44 units on a scale